InspireMD, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.0M | $7.0M | $6.2M | $5.2M | $4.5M |
| Cost of revenue | $6.3M | $5.5M | $4.4M | $4.1M | $3.7M |
| Gross profit | $2.6M | $1.5M | $1.8M | $1.1M | $754,000 |
| Research and development | $15.0M | $13.6M | $8.0M | $7.8M | $5.2M |
| Operating expenses | $52.3M | $35.0M | $22.9M | $19.8M | $15.5M |
| Operating income | -$49.6M | -$33.5M | -$21.1M | -$18.7M | -$14.7M |
| Pretax income | -$48.7M | -$31.9M | -$19.9M | -$18.5M | -$14.9M |
| Income tax expense | $63,000 | $59,000 | $65,000 | $28,000 | $45,000 |
| Net income | -$48.8M | -$32.0M | -$19.9M | -$18.5M | -$14.9M |
| Balance Sheet | |||||
| Cash and equivalents | $8.9M | $18.9M | $9.6M | $4.6M | $12.0M |
| Current assets | $61.5M | $40.5M | $44.2M | $21.3M | $37.1M |
| Total assets | $69.4M | $46.8M | $47.6M | $24.7M | $39.7M |
| Current liabilities | $10.7M | $7.7M | $6.0M | $5.1M | $4.3M |
| Total liabilities | $14.2M | $10.7M | $8.1M | $7.3M | $6.2M |
| Stockholders' equity | $55.2M | $36.1M | $39.5M | $17.4M | $33.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$35.1M | -$21.9M | -$16.4M | -$15.5M | -$13.2M |
| Depreciation and amortization | $476,000 | $280,000 | $232,000 | $188,000 | $161,000 |
| Stock-based compensation | $12.3M | $10.1M | $4.5M | $2.4M | $1.6M |
| Capital expenditure | $1.7M | $1.4M | $381,000 | $473,000 | $344,000 |
| Free cash flow | -$36.8M | -$23.3M | -$16.8M | -$16.0M | -$13.6M |
Shares outstanding 46.8M · Free float 48.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.